Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 800 · Balance 2,503 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. Row 2 · 2026-08-10 · Sale · Disposed 800 · Balance 1,703 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $376.69 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 800 · Balance 0 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F2: The stock option vested in three equal annual installments, commencing one year after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
F2: The stock option vested in three equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $616.19 | $61,002.81 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 11 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 80 | $615.28 | $49,222.40 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 10 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $613.03 | $3,065.15 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 9 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 265 | $612.52 | $162,317.80 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 8 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 265 shares of Company stock on June 10, 2020 at prices ranging from $612.12 to $612.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 164 | $611.46 | $100,279.44 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 7 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,092 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 164 shares of Company stock on June 10, 2020 at prices ranging from $611.06 to $611.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 202 | $610.41 | $123,302.82 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 6 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 202 shares of Company stock on June 10, 2020 at prices ranging from $610.18 to $610.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 161 | $609.48 | $98,126.28 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 5 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 161 shares of Company stock on June 10, 2020 at prices ranging from $609.31 to $609.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 330 | $608.62 | $200,844.60 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 4 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,619 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 330 shares of Company stock on June 10, 2020 at prices ranging from $608.15 to $608.9. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 251 | $607.64 | $152,517.64 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 251 shares of Company stock on June 10, 2020 at prices ranging from $607.02 to $607.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 149 | $606.64 | $90,389.36 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 149 shares of Company stock on June 10, 2020 at prices ranging from $606.23 to $606.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 10, 2020 at each separate price. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,706 | $391.92 | $668,615.52 |
DisclosureSEC source: 0001708138-20-000072 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,118 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001708138-20-000050 · edgardoc.xml · derivative · entry 7 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,235 Underlying: Common Stock · 5,118 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13 | $569.20 | $7,399.60 |
DisclosureSEC source: 0001708138-20-000050 · edgardoc.xml · nonDerivative · entry 6 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 609 | $568.37 | $346,137.33 |
DisclosureSEC source: 0001708138-20-000050 · edgardoc.xml · nonDerivative · entry 5 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656 F4 · price: Represents volume-weighted average price of sales of 609 shares of Company stock on May 7, 2020 at prices ranging from $568.05 to $568.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 646 | $567.58 | $366,656.68 |
DisclosureSEC source: 0001708138-20-000050 · edgardoc.xml · nonDerivative · entry 4 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,265 F3 · price: Represents volume-weighted average price of sales of 646 shares of Company stock on May 7, 2020 at prices ranging from $567.20 to $567.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,128 | $566.37 | $1,205,235.36 |
DisclosureSEC source: 0001708138-20-000050 · edgardoc.xml · nonDerivative · entry 3 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,911 F2 · price: Represents volume-weighted average price of sales of 2,128 shares of Company stock on May 7, 2020 at prices ranging from $566.00 to $566.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,722 | $565.64 | $974,032.08 |
DisclosureSEC source: 0001708138-20-000050 · edgardoc.xml · nonDerivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,039 F1 · price: Represents volume-weighted average price of sales of 1,722 shares of Company stock on May 7, 2020 at prices ranging from $565.43 to $565.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,118 | $391.92 | $2,005,846.56 |
DisclosureSEC source: 0001708138-20-000050 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001708138-20-000006 · edgardoc.xml · derivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000006 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001708138-19-000006 · edgardoc.xml · derivative · entry 2 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-19-000006 · edgardoc.xml · nonDerivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:14 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-18-000004 · edgardoc.xml · derivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,438 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000001 · edgardoc.xml · derivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,438 Underlying: Common Stock · 2,438 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 09, 2016 Filed Sep 12, 2016 20:25 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,353 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001104659-16-144227 · a4.xml · derivative · entry 1 Zoghbi Huda Y · CIK 0001681643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,353 Underlying: Common Stock · 15,353 shares Expires 2026-09-09 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.